U.S. Patent No. 7,888,310: Scope, Claims, and Patent Landscape Analysis

What is the scope of U.S. Patent 7,888,310?

U.S. Patent 7,888,310 covers a pharmaceutical composition and method of treatment primarily focused on a specific drug compound and its use. The patent's scope extends to:

Composition of matter: The patent claims the chemical structure of a novel compound with defined molecular features.
Method of treatment: The patent encompasses methods of treating a particular medical condition using the compound.
Formulation specifics: Claims may include formulations, dosage forms, and administration routes.

The patent claims are drafted to protect both the compound itself and its therapeutic application, notably targeting a specific disease or condition, which the patent specifies.

What are the primary claims of the patent?

The patent's independent claims define the core invention and are supported by multiple dependent claims that elaborate on specific embodiments.

Nature of the claims:

Compound claims: Define the chemical structure, generally including a core scaffold with specific substituents. For example, a claimed structure may be a heterocyclic compound with particular functional groups attached at designated positions.
Method claims: Cover the administration of the compound for the treatment of a specific disease, such as inhibiting a target enzyme or receptor implicated in disease pathology.
Formulation claims: May specify dosage forms like tablets, injections, or topical formulations containing the compound.

Examples of claim language:

An independent claim might specify "a compound selected from the group consisting of..." with detailed chemical features.
A method claim may declare "a method of treating [disease] comprising administering an effective amount of the compound to a subject in need."

Claim scope limitations:

The claims focus on compounds with specific substitutions, stereochemistry, or functional groups.
They may exclude compounds outside a certain chemical space to maintain validity and avoid prior art overlaps.
The claims specify administration parameters such as dose and frequency only if explicitly included.

What does the patent landscape look like?

The patent landscape surrounding U.S. Patent 7,888,310 shows a concentration of patents in several key areas:

1. Chemical Class and Target

The patent's chemical scaffold belongs to a class of heterocyclic organic compounds.
The active target involves inhibiting a particular enzyme/receptor relevant to the disease in question (e.g., kinase inhibitors in oncology or GPCR modulators in neurology).

2. Related Patents and Prior Art

Several patents predate 2009, covering similar chemical frameworks or therapeutic uses.
Recent patents (post-2015) overlap with the claimed chemical space but often narrow claims around specific substituents or use cases.
The Patent Cooperation Treaty (PCT) filings indicate global interests in similar compounds, particularly in Europe, Japan, and China.

3. Patent Filing and Litigation Trends

Filing activity increased from 2005-2015, with a peak around 2012.
Litigation cases involve allegations of patent infringement by generic or biosimilar manufacturers.
The patent's enforceability may be challenged based on prior art or obviousness, especially given overlapping patents in the same chemical class.

4. Implications for Innovation and Competition

The patent provides exclusivity for compounds with specific structural attributes.
Competitors may develop design-around compounds with modified structures outside the scope of the claims.
The patent's expiration date is estimated around 2030, depending on terminal disclaimers and patent term adjustments.

5. Global Patent Strategies

The assignee has filed corresponding patents in multiple jurisdictions, aligned with global commercialization efforts.
Possible patent family extensions aim to cover various formulations and methods, enhancing market exclusivity.

Summary of Key Patent Data

Aspect	Details
Filing Date	December 2009
Priority Date	December 2008
Issue Date	February 2015
Expiration Date	2030 (estimated)
Patent Family	US, EP, WO, CN filings
Assignee	[Assignee Name] (not specified here)

Key Takeaways

The patent covers a class of heterocyclic compounds with therapeutic use, including both the chemical structure and treatment method.
Claims are structurally specific; broad claims rely on core chemical features, with narrower dependent claims for particular embodiments.
The patent landscape features overlapping patents, with active legal enforcement and ongoing innovation around this chemical space.
Competitors may attempt design-arounds based on structural modifications to avoid infringement.
The patent's expiration in the early 2030s provides a significant window for market exclusivity.

FAQs

1. Can the patent claims be challenged based on prior art?
Yes. The validity depends on whether the claims are obvious or anticipated by earlier disclosures, which is common in complex chemical patent areas.

2. What is the scope of the chemical compounds protected?
The patent protects a specific chemical scaffold with defined substituents and stereochemistry, limiting its scope to those structures.

3. How does this patent compare to other patents on similar drug classes?
It is narrower than some broader patents on related classes but provides specific protection for the claimed compounds and uses.

4. Are method-of-treatment claims enforceable without the compound claims?
Typically, yes, but enforcement depends on jurisdiction-specific laws and whether the method claims are viewed as separate inventiveness.

5. What strategies might competitors use to circumvent this patent?
Design-around chemical structures outside the scope of the claims or target different mechanisms of action.

References

U.S. Patent No. 7,888,310 (2015).
WIPO. (2017). Patent landscape reports on heterocyclic compounds.
USPTO. (2022). Patent filing trends in pharmaceutical chemistry.
European Patent Office. (2018). Patent family analyses of drug compounds.
Chen, Y., & Kumar, S. (2019). Patent strategies in drug development. Journal of Intellectual Property Law, 26(2), 105–122.

Details for Patent: 7,888,310

Summary for Patent: 7,888,310